€ 1.2
Key Takeaways
Risk factor
High price volatility
Profitability factor
Very low or no dividends
About
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, undervalued o
Target Price
The average target price of PHARM.AS is 2.1 and suggests 73% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
